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Among Survivors of Ebola Virus Disease From the 1995 
Ebola Outbreak in Kikwit, Democratic Republic of Congo: 
A Cross-sectional Study
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Jean Jacques Muyembe-Tamfum,5 and Anne W. Rimoin2
1School of Medicine, University of California, San Francisco, and 2School of Public Health, University of California, Los Angeles; 3Department of Genetic Medicine Research, Children’s Research 
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Background. Clinical sequelae of Ebola virus disease (EVD) have not been described more than 3 years postoutbreak. We exam-
ined survivors and close contacts from the 1995 Ebola outbreak in Kikwit, Democratic Republic of Congo (DRC), and determined 
prevalence of abnormal neurological, cognitive, and psychological findings and their association with EVD survivorship.
Methods. From August to September 2017, we conducted a cross-sectional study in Kikwit, DRC. Over 2 decades after the EVD 
outbreak, we recruited EVD survivors and close contacts from the outbreak to undergo physical examination and culturally adapted 
versions of the Folstein mini-mental status exam (MMSE) and Goldberg anxiety and depression scale (GADS). We estimated the 
strength of relationships between EVD survivorship and health outcomes using linear regression models by comparing survivors 
versus close contacts, adjusting for age, sex, educational level, marital status, and healthcare worker status.
Results. We enrolled 20 EVD survivors and 187 close contacts. Among the 20 EVD survivors, 4 (20%) reported at least 1 
abnormal neurological symptom, and 3 (15%) had an abnormal neurological examination. Among the 187 close contacts, 14 (11%) 
reported at least 1 abnormal neurologic symptom, and 9 (5%) had an abnormal neurological examination. EVD survivors had lower 
mean MMSE and higher mean GADS scores as compared to close contacts (MMSE: adjusted coefficient: −1.85; 95% confidence 
interval [CI]: −3.63, −0.07; GADS: adjusted coefficient: 3.91; 95% CI: 1.76, 6.04).
Conclusions. EVD survivors can have lower cognitive scores and more symptoms of depression and anxiety than close contacts 
more than 2 decades after Ebola virus outbreaks.
Keywords. Ebola virus disease; survivors; Democratic Republic of Congo; clinical findings.
Despite the more than 34 reported Ebola outbreaks since 1976 
[1], we are only beginning to understand the long-term health 
consequences of survivorship of Ebola virus disease (EVD). 
A large proportion of EVD survivors experience ongoing, debil-
itating sequelae, which has been described in the short-term as 
a “post-EVD clinical syndrome” [2, 3]. Part of this clinical syn-
drome includes a spectrum of abnormal neurological, cogni-
tive, and psychological findings, ranging from memory loss and 
meningoencephalitis to depressive symptoms, and these findings 
have been documented as early sequelae among EVD survivors 
[3–8]. A study conducted 29 months after the 2003 outbreak in 
Bundibugyo, Uganda, reported neurological and cognitive find-
ings among EVD survivors [6], and a study conducted 1 month 
after the 1995 outbreak in Kikwit, Democratic Republic of Congo 
(DRC), reported psychological sequelae from EVD such as shame, 
anxiety, stigma, and rejection by family, friends, and neighbors [9], 
which have made reintegration challenging for survivors [10–12].
Older EVD outbreaks such as the 1995 outbreak in Kikwit 
may cause trauma and result in a significant burden of unrecog-
nized, long-term mental health issues, such as depression and 
anxiety. In contrast to the West African outbreak of 2013–2016 
[12, 13], international agencies did not provide clinical, psy-
chosocial, or economic services to these older cohorts of EVD 
survivors to support them through their recovery and reinte-
gration [14]. As a result, psychological consequences may be 
unresolved, whereas new psychological consequences may even 
occur from disability related to EVD clinical sequelae such as 
complications of uveitis [13, 15–17]. EVD-related neurolog-
ical and cognitive sequelae might also occur within the same 
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individuals, and post-traumatic syndromes have the potential 
to develop into chronic diseases.
The pathogenesis of neurological and cognitive sequelae is 
not well understood and, in rare circumstances, meningoen-
cephalitis from viral persistence in the central nervous system 
(CNS) may have a role in early sequelae [8, 18]. Although neu-
rological sequelae such as memory loss and confusion were 
reported more than 2  years after the 2003 Ugandan outbreak 
[6], it is unclear whether many neurological and cognitive 
sequelae are the result of CNS pathology or are manifesta-
tions of post-traumatic syndromes. This Ugandan study and 
the majority of others relied on self-reports rather than clini-
cal examinations [5, 6]. Our understanding of the pathophysi-
ological mechanisms of post-EVD sequelae is limited to uveitis 
and meningoencephalitis [19]. Thus, post-traumatic syndromes 
may play an underappreciated role in post-EVD syndrome and 
become complications leading to long-term neurological, cog-
nitive, and psychological sequelae.
More than 2 decades after the 1995 Kikwit EVD outbreak, we 
conducted a study to describe the prevalence of adverse neuro-
logical, cognitive, and psychological findings and determine the 
association of EVD with these health outcomes.
METHODS
Ethics Statement
The study protocol was approved by the Institutional Review 
Boards at the Fielding School of Public Health at University 
of California, Los Angeles, in Los Angeles, California, USA, 
and the Kinshasa School of Public Health in Kinshasa, DRC. 
Written informed consent was obtained from all participants.
Study Design and Participants
From August to September 2017, we conducted a cross-sec-
tional study of EVD survivors and their close contacts from 
the 1995 EVD outbreak in Kikwit. During the outbreak, there 
were 315 EVD cases (89 laboratory-confirmed by presence of 
detectable antigen or immunoglobulin M [IgM] antibodies; 
226 probable cases by World Health Organization [WHO] 
EVD case definition). The case fatality rate was 81%; thus, 61 
cases survived EVD [20]. After the outbreak, these reported 
EVD survivors created the Kikwit Ebola Survivor Association. 
More than 2 decades later when we conducted our study, this 
organization provided us with a list of 42 EVD survivors who 
were reported EVD cases during the 1995 Ebola outbreak. Of 
these 42 members listed as part of the Kikwit Ebola Survivor 
Association, only 20 survivors were living in Kikwit and the sur-
rounding area. We attempted to recruit these 20 survivors. Our 
social mobilization team announced recruitment through the 
Kikwit Ebola Survivor Association, media, community sensiti-
zation, and healthcare facilities in Kikwit and the surrounding 
area. We found that this list included survivors living in remote 
locations where there was no cell phone or radio coverage who 
were unable to be contacted. Thus, we enrolled an exhaustive, 
convenience sample from this list and defined them as reported 
EVD survivors.
During recruitment, there were a few individuals who 
self-identified as EVD survivors who reported direct contact 
with an EVD case and symptoms consistent with acute EVD 
during the post-exposure period; they met WHO EVD case 
definition [21] but were not on the list of “reported survivors” 
from the Kikwit Ebola Survivor Association. Unrecognized 
EVD cases and unknown sources of Ebola virus infection 
were reported during the 1995 Kikwit outbreak and have since 
been increasingly described as a public health issue of signif-
icance, particularly during the 2013–16 West Africa outbreak 
[22–25]. Based on our experiences in outbreak response work 
and unpublished findings from the 2013–16 West Africa out-
break, we rationalized that from the biosocial perspective, 
individuals who were perceived as EVD survivors in the com-
munity, regardless of being in a registry, were at risk for neuro-
logical, cognitive, and particularly psychological findings. We 
defined these individuals as self-reported EVD survivors. We 
included reported and self-reported EVD survivors in our study 
and defined them as EVD survivors.
Close contacts were included in the study if they reported 
direct contact with an EVD case and reported that this contact 
event occurred during the 1995 EVD outbreak in Kikwit. Direct 
contact was defined as directly touching body fluids (including 
but not limited to blood, saliva, mucus, vomit, urine, or feces) 
from an infected person (alive or dead) and having touched 
someone’s eyes, nose, or mouth or an open cut, wound, or abra-
sion [26]. Recruitment of close contacts primarily occurred 
using 2 different methods; EVD survivors identified up to five 
individuals who were in contact with them during their acute ill-
ness, and in collaboration with the leadership of Kikwit General 
Hospital, we obtained a list of healthcare workers who worked 
in Ebola care facilities during the 1995 outbreak in Kikwit and 
the surrounding vicinity. For individuals identified by EVD sur-
vivors, contact mostly occurred in the community and partic-
ularly in households of EVD survivors. For healthcare workers, 
contact mostly occurred in healthcare settings.
Each participant responded to a questionnaire and received a 
physical examination. The sociodemographic and epidemiolog-
ical questionnaire was administered by study staff who were not 
healthcare providers. We recruited and trained Congolese doc-
tors, who were medical officers, to perform the medical history 
and physical examination and to administer the cognitive and 
psychological questionnaires. Doctors with specialty training in 
Ebola clinical sequelae were involved in the training and super-
vision of data collection.
Data Collection
The outcome measurements included neurological, cognitive, 
and psychological findings. We used self-reported symptoms 
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and physical examinations to assess for abnormal neurological 
findings. Abnormal neurological symptoms were defined as 
the self-reported symptoms that were endorsed from a 12-item 
checklist. The list of symptoms included headache, syncope, 
dizziness, vertigo, seizures, diplopia, paresthesia, paraly-
sis, weakness in any limbs, tremor, ataxia, and memory loss. 
Abnormal neurological examinations were defined as physical 
exam findings of the neurologic system that were assessed from 
an 8-item checklist. The exam assessed speech, tremor, reflexes, 
cranial nerves, focal weakness, gait/balance, sensory, and other 
abnormal findings (free response).
Cognitive findings were defined by the Folstein mini-mental 
status exam (MMSE) [27]. Cronbach’s alpha for the MMSE was 
0.58. We used Goldberg anxiety and depression scale (GADS), 
which was developed from 36 items in the Psychiatric Assessment 
Schedule [28] and has been used in several community-based 
studies of older adults [29]. This assessment tool was validated 
in a 2012 study in Kinshasa, DRC [30]. GAD was an 18-item 
scale that consisted of a 9-item depressive symptom subscale and 
9-item anxious symptoms subscale. Cronbach’s alpha for GADS 
was 0.86, whereas the depressive symptom subscale and anxious 
symptoms subscale were 0.86 and 0.84, respectively. EVD-related 
stigma was defined based on a 7-item index adapted from the 
People Living with HIV/AIDS Stigma for EVD survivors of the 
West Africa outbreak [31]. Cronbach’s alpha for the stigma scale 
was 0.76. Confounders were identified from the questionnaire 
and included current age, sex, educational level, marital status, 
and prior healthcare worker status (during the outbreak).
Statistical Analyses
We described the characteristics and neurological, cognitive, 
and psychological findings of participants. Age, MMSE (scale, 
0–30), GADS (scale, 0–18), GADS subscales (each scale, 0–9) 
and the 7-item EVD-related stigma index (scale, 0–7) were con-
tinuous variables. Sex, educational level, marital status, and type 
of occupation were dichotomized. Characteristics among EVD 
survivors and close contacts were assessed for differences using 
Fischer exact or t-tests. We assessed the association between 
EVD survivorship (EVD survivors vs close contacts) and health 
outcomes and used linear regression models in bivariate and 
multivariate analyses adjusting for the potential confounders of 
age, sex, educational level, marital status, and being a health-
care worker. Our threshold for a statistically significant finding 
was P < .05. We conducted these analyses with EVD survivors 
(self-reported and reported), as well as reported EVD survivors. 
We performed sensitivity analyses for EVD survivors, using a 
propensity score model (Supplementary Material 1 and 2) and 
a sensitivity analysis for close contacts by comparing character-
istics of individuals identified by EVD survivors versus list of 
healthcare workers (Supplementary Material 3). Analyses were 
performed using STATA/IC 13.1 (STATA Corporation, College 
Station, TX) and R (version 3.2.3).
RESULTS
Twenty EVD survivors and 187 close contacts were enrolled. 
Among these 20 EVD survivors, the mean age was 53.2 (95% 
confidence interval [CI], 48.1–58.3). The majority (70%) was 
female, whereas nearly half (45%) had completed only pri-
mary school or had no formal education. Nine (45%) were 
married, and 8 (40%) were healthcare workers during the out-
break. Comparing these characteristics among EVD survivors 
and close contacts, there was a trend of a difference in educa-
tional level (Table 1). In sum, 14 (70%) of the 20 EVD survivors 
were reported cases. There was no difference in characteristics 
among these groups (Table 1).
Description of Neurological, Cognitive, and Psychological Findings
Among EVD survivors, 4 (20%) reported at least 1 abnormal 
neurological symptom, which included headache (15%), vertigo 
(15%), paresthesia (5%), weakness in any limbs (5%), tremor 
(5%), and ataxia (5%). Three (15%) survivors had an abnormal 
neurological examination, which included the following find-
ings among survivors: tremor (10%), gait/balance disturbance 
(10%), speech abnormality (5%), cranial nerve abnormality 
(5%), focal weakness (5%), and sensory deficit (5%). Mean 
MMSE score was 20.6 (95% CI, 17.1–23.6), and mean GADS 
score was 8.0 (95% CI, 5.4–10.6). Mean GADS subscale score 
for depressive symptoms was 3.4 (95% CI, 2.1–4.6) and mean 
GADS subscale score for anxious symptoms was 4.7 (95% CI, 
3.2–6.1). Thirteen (65%) reported experiencing at least 1 item 
of EVD-related stigma in the 6 months after outbreak, and one 
individual experienced EVD-related stigma in the 6  months 
prior to the interview (Table 1).
Among close contacts, 14 (11%) reported at least 1 abnor-
mal neurologic symptom, which included headache (10%), ver-
tigo (4%), paresthesia (2%), weakness in any limbs (2%), ataxia 
(2%), and memory loss (2%). Nine (5%) had an abnormal neu-
rological examination, which included the following findings 
among contacts: abnormal reflexes (4%), cranial nerve abnor-
mality (4%), gait/balance disturbance (3%), tremor (2%), sen-
sory deficit (2%), and focal weakness (1%). Mean MMSE score 
was 23.5 (95% CI, 22.8–24.1). Mean GADS score was 4.1 (95% 
CI, 3.3–4.9), and mean GADS subscale score for depressive 
symptoms was 1.6 (95% CI, 1.2–2.0) and mean GADS subscale 
score for anxious symptoms was 2.5 (95% CI, 2.0–2.9) (Table 1).
Associations With Neurological, Cognitive, and Psychological Findings
In unadjusted analyses, EVD survivors had a statistically lower 
mean MMSE score, higher mean GADS score, and higher mean 
GADS subscale score as compared to close contacts. After multi-
variable adjustment, EVD survivors were at risk of a lower mean 
MMSE score as compared to close contacts (adjusted coefficient: 
−1.85; 95% CI: −3.63, −0.07). EVD survivors were at risk of a 
higher mean GADS score as compared to close contacts (adjusted 
coefficient: 3.91; 95% CI: 1.76, 6.04). EVD survivors also had 
Clinical Findings Two Decades Post-Ebola • CID 2019:68 (15 April) • 1391
higher mean GAD subscale scores for depressive symptoms 
(adjusted coefficient: 1.80; 95% CI: 0.70, 2.90) and for anxious 
symptoms (adjusted coefficient: 1.98; 95% CI: 0.75, 3.21) than 
close contacts. A similar pattern of associations, some of which 
had stronger magnitudes, was also observed when comparing 
reported EVD survivors to close contacts. There were no signifi-
cant associations between survivorship and abnormal neurolog-
ical symptoms or abnormal neurological examinations (Table 2).
DISCUSSION
This is the first follow-up study of EVD survivors and close con-
tacts from the 1995 Kikwit outbreak since 1997 [5]. Although 
adverse neurological, cognitive, and psychological findings 
have been described shortly after surviving EVD, we found 
EVD survivors to have reduced general cognition and more 
symptoms of depression and anxiety than close contacts more 
than 2 decades after the Kikwit outbreak. Based on our small 
sample, there was no evidence of significantly elevated risk for 
other abnormal neurological findings or persistent EVD-related 
stigma. These findings were consistent between self-reported 
and reported EVD survivors. Given the small size of the EVD 
survivor cohort from Kikwit, similar studies with larger sample 
sizes will be beneficial to expand these findings.
More than 2 decades after the outbreak, our findings suggest 
that EVD survivors continue to be in need of psychosocial sup-
port and mental health intervention. The majority of reported and 
self-reported EVD survivors in our study recalled experiences of 
EVD-related stigma and discrimination. Even if not still ongo-
ing, community perceptions of survivorship as well as outbreak 
Table 2. Association of Ebola Virus Disease (EVD) Survivorship With Neurological, Cognitive, and Psychological Findings (EVD Survivors, N = 20; Reported 
EVD Survivors, N = 14; Close Contacts, N = 187). 
Outcomes
Adjusted Coefficient  
for EVD Survivors (95% CI) P Values
Adjusted Coefficient for  
Reported EVD Survivors (95% CI) P Values
Abnormal neurologic symptoms 0.62 (−0.67–1.92) .35 0.51 (−0.99–2.00) .51
Abnormal neurological examination 1.57 (−0.21–3.35) .08 1.11 (−1.10–3.33) .32
MMSEa −1.85 (−3.63–-0.07) .04 −2.10 (−4.05–-0.14) .04
GADS b 3.91 (1.76–6.04) <.01 5.89 (3.41–8.37) <.01
GADS: Depressive symptoms subscale 1.80 (0.70–2.90) <.01 2.77 (1.47–4.07) <.01
GADS: Anxious symptoms subscale 1.98 (0.75–3.21) <.01 3.04 (1.61–4.47) <.01
Covariates used to adjust for confounding included age, sex, educational level, marital status, and being a healthcare worker. P values are described for adjusted models, and bold indicates 
a value <.05.
Abbreviations: CI, confidence interval; EVD, Ebola virus disease; GADS, Goldberg anxiety and depression scale; MMSE, mini-mental status exam.
aFolstein MMSE, scale 0–30.
bGADS, scale 0–18.
Table 1. Characteristics of Ebola Virus Disease (EVD) Survivors (N = 20), Reported EVD Survivors (N = 14) and Close Contacts (N = 187) and Prevalence of 
Neurological, Cognitive, and Psychological Findings
Characteristics
EVD Survivors
Reported EVD 
Survivors Close Contacts
P Values for 
Survivors
P Values for 
Reported 
SurvivorsN = 20 % or 95% CI N = 14 % or 95% CI N = 187 % or 95% CI
Current age, years (mean) 53.2 48.1–58.3 53.4 46.1–60.6 53.5 51.6–55.3 .94 .98
Female 14 70.0 12 85.7 99 52.9 .16 .02
Education: none or primary 9 45.0 8 57.1 44 23.5 .06 .01
Married at present 9 50.0 6 42.9 117 62.6 .23 .16
Healthcare worker in 1995 8 44.4 5 35.7 83 44.4 .82 .59
Abnormal neurological symptoms 4 20.0 3 21.4 14 10.9
Abnormal neurological examination 3 15.0 2 14.0 9 4.8
MMSEa (mean) 20.6 17.6–23.6 20.1 16.4–23.7 23.5 22.8–24.1
GADSb (mean) 8.0 5.4–10.6 9.8 7.1–12.5 4.1 3.3–4.9
GADS: depressive symptoms sub-scale (mean) 3.4 2.1–4.6 4.2 2.7–5.8 1.6 1.2–2.0
GADS: anxious symptoms sub-scale (mean) 4.7 3.2–6.1 5.5 4.2–7.0 2.5 2.0–2.9
Any EVD-related stigma in the 6 months after 
the outbreak?
13 65.0 9 64.3
Any EVD-related stigma in the past 6 months? 1 5.0 0 0
Bold indicates a P value <.05.
Abbreviations: CI, confidence interval; EVD, Ebola virus disease; GADS, Goldberg anxiety and depression scale; MMSE, mini-mental status exam.
aFolstein MMSE; scale 0–30.
bGADS; scale 0–18.
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experiences may have contributed to cognitive and psycholog-
ical findings. In our conversations with these survivors, many 
experienced post-traumatic syndromes during the outbreak and 
post-outbreak period without receiving adequate care. Other than 
the West Africa outbreak, international agencies have not pro-
vided free services to EVD survivors. There may be large, unad-
dressed needs in this field. Moreover, these psychosocial needs 
may be ongoing for long periods of time for some EVD survivors. 
Studies assessing the neurological, cognitive, and psychological 
health of EVD survivors across all prior outbreaks are needed.
We conducted analyses with EVD survivors and their sub-
group of reported EVD survivors as well as with propensity 
score models and the consistency of findings across outcomes 
and subgroups was reassuring that our findings are not due to 
type I  or II errors. Due to the very small numbers of self-re-
ported EVD survivors, we were unable to calculate effect esti-
mates for this group without including reported EVD survivors. 
Given that the study was cross-sectional, we are unable to deter-
mine when the outcomes occurred or how long they persisted. 
No data were available for comparison related to the pre-out-
break, outbreak or early post-outbreak periods. We used GADS 
because it was adapted to the DRC; GADS is a measure of 
symptoms and not a DSM-5 diagnosis. Our measurement tools 
(scales and index) had high Cronbach’s alpha scores, indicat-
ing an acceptable level of internal consistency. These tools have 
been validated in our settings including sub-Saharan Africa but 
were not validated specifically for this study population. There 
may have also be recall error for some of the measurements 
such as having ever experienced stigma. Attempts were made 
to limit recall error by designing questions to report responses 
that were current at the study visit, particularly for clinical ques-
tions. Furthermore, our findings represent a small population 
of older EVD survivors and cannot necessarily be generalized 
to other EVD survivor populations. The use of close contacts as 
a control group served as an important strength in our method-
ology to determine the predictors of EVD survivorship amongst 
neurological, cognitive, and psychological data.
This study highlights general cognition and symptoms of 
depression and anxiety as areas where there may be long-term 
health needs of >10 000 EVD survivors from the 2013–16 West 
Africa outbreak and for the EVD survivors of >33 other EVD 
outbreaks. More studies are needed to understand other long-
term health outcomes of EVD survivors, but our findings are 
a call to action for the scientific community, as well as inter-
national and government agencies to work in collaboration to 
understand and address the long-term needs of EVD survivors 
no matter the size of the outbreak.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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